APAC personalised nutrition firm reveals sales success on the back of B2B partnerships
Imagene Labs offers tailor-made nutrition and fitness supplement regimes based on findings from customers' saliva DNA tests. It also offers a skincare package.
Director of product development Alina Uchida said the firm was having success through B2B and B2C models.
On the B2B side, she said the company distributes products via wellness centres, gyms and fitness facilities, beauty and spa operations, aesthetic centres, private hospitals, and insurance firms.
In terms of B2C, individual consumers are able to access Imagene Labs’ genetic testing service and products on its website.
The B2B offering is performing particularly well, said Uchida, with partnerships contributing to a 76% overall increase in customer growth in Q3 2017 compared with Q2.
Revenues nearly doubled over the same period.
"Our best-selling test is oriLIFE," she said. "This is where customers get all three tests, reports, customised facial serum and customised supplements."
"Since it's a once-in-a-lifetime test, consumers see the value of getting all reports in one go."
The supplements are provided in microtab format, and can be added to smoothies and beverages.
In the past 12 months, the firm has launched in Malaysia, Hong Kong, China and Thailand. Vietnam will soon follow, and come Q4, the company will launch its first finished product for retail in Australia.
The cognitive health range features two products; one formulated for students and working adults, the other for seniors.
It is a once-daily supplement that features a proprietary sage extract with benefits for cognitive function. The sage extract will be supplied by Sibelius, a University of Oxford spin-off which we reported on earlier this year.
Uchida said this development was in line with the firm's aim to build a strong portfolio of innovative brands.
In the cosmetics sector, the company already has Kaizen, a skin, hair and body care range featuring fermented micro-algae derived from Japan's onsens.
Uchida added: "We are receiving a lot of interest from consumers and investors. We have hit upon something that has great potential."